{"id":27182,"date":"2021-06-23T10:48:56","date_gmt":"2021-06-23T10:48:56","guid":{"rendered":"https:\/\/news.cancerresearchuk.org\/?p=23244"},"modified":"2024-11-03T15:14:52","modified_gmt":"2024-11-03T15:14:52","slug":"trialling-a-new-way-to-boost-car-t-cell-therapy","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/trialling-a-new-way-to-boost-car-t-cell-therapy\/","title":{"rendered":"Trialling a new way to boost CAR T-cell therapy"},"content":{"rendered":"
\"3D<\/p>\n

3D rendering of blood cancer<\/p>\n<\/div>\n

Cancer Research UK is collaborating with Aleta Biotherapeutics<\/a> (Aleta) to trial a new therapy that \u2018reboots\u2019 a treatment for some people with blood cancer whose cancer starts to come back.<\/p>\n

The new therapy, called ALETA-001, aims to boost a treatment called CAR T-cell therapy<\/a>, which takes some of a patient\u2019s immune cells and alters them to attack cancer.<\/p>\n

Cancer Research UK\u2019s Centre for Drug Development will fund, sponsor and conduct the clinical trial of ALETA-001, which will involve people with B cell lymphoma and leukaemia.<\/p>\n

Nigel Blackburn, Cancer Research UK\u2019s director of drug development, said this is a landmark collaboration for Cancer Research UK.<\/p>\n

\u201cIt\u2019s the first-in-human trial for a new drug that reboots CAR T-cell therapy, and we look forward to progress its early clinical development with Aleta.\u201d<\/p>\n

Rebooting CAR T-cell therapy<\/h2>\n
\n

CAR T-cell therapy works by taking some of a patient\u2019s T cells and altering them to recognise a particular protein found on lymphoma and leukaemia cells, called CD19. After a few weeks, these cells are then fed back into the bloodstream and attack cancer cells.<\/p>\n<\/div>\n

\u201cCAR T-cell therapy has been transformative in treating patients<\/a> with hard-to-treat blood cancers, but many will see their cancer return and treatment options begin to run out,\u201d said Blackburn.<\/p>\n

Around half of the patients treated with CAR T-cell therapy relapse, mostly because their cancer cells stop producing the CD19 protein that CAR T-cells are looking for.<\/p>\n

When this happens, patients have few other options.<\/p>\n

ALETA-001 acts as a \u2018reboot\u2019 for CAR T-cell therapy, attaching to a different protein called CD20 and \u2018recoating\u2019 the cancer cell with CD19. The CAR T-cells can then recognise and attack the cancer cells again.<\/p>\n

\u201cALETA-001 uses a simple yet elegant method to redirect a patient\u2019s circulating CD19 CAR T-cells against cancer cells expressing CD20, and we hope this could be a new treatment avenue for blood cancer,\u201d said Blackburn.<\/p>\n

Taking ALETA-001 to the clinic<\/h2>\n

The first trial will enrol patients with B cell lymphoma or leukaemia who have received CD19 CAR T-cell therapy but did not achieve a complete response or whose cancer has come back.<\/p>\n

Led by a team at The Christie NHS Foundation Trust in Manchester, it will be the first time that this type of therapy has ever been tested in humans.<\/p>\n

A key aim of the trial is to find out the right dosage of ALETA-001. After this, it will be move into a much bigger trial in the US involving people with diffuse large B cell lymphoma<\/a>.<\/p>\n

This second trial will be designed to support potential accelerated approval of ALETA-001 for cancer patients.<\/p>\n

Paul Rennert, President, co-founder and chief scientific officer of Aleta Biotherapeutics, said: \u201cThere is an urgent need to develop new therapies that can help people with B cell cancers, such as lymphoma and leukaemia, whose cancer has progressed after treatment with CD19 CAR T-cell therapy.\u201d<\/p>\n

\u201cWe look forward to working with Cancer Research UK\u2019s exceptional network of experienced clinical trial investigators and researchers to conduct the trial.\u201d<\/p>\n

More on this topic<\/h3>\n<\/p>\n

Source<\/a><\/p>","protected":false},"excerpt":{"rendered":"

3D rendering of blood cancer Cancer Research UK is collaborating with Aleta Biotherapeutics (Aleta) to trial a new therapy that \u2018reboots\u2019 a treatment for some people with blood cancer whose cancer starts to come back. The new therapy, called ALETA-001, aims to boost a treatment called CAR T-cell therapy, which takes some of a patient\u2019s […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-27182","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/27182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=27182"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/27182\/revisions"}],"predecessor-version":[{"id":45272,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/27182\/revisions\/45272"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=27182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=27182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=27182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}